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Summary Expression of the oestrogen-regulated pNR-2/pS2 protein has been studied in paraffin sections of a
series of 172 primary breast cancers using an immunohistochemical technique. Positive staining of tumour cells
was found in 117 tumours (68%): most of these tumours contained only a small proportion of positive cells.
pNR-2 immunohistochemical staining correlated positively and significantly with the presence of oestrogen
receptor. Mean percentages of pNR-2 positive cells were lower in tumours from postmenopausal women.
Smaller, better differentiated tumours were significantly more likely to stain positively for pNR-2. The
percentages of pNR-2 positive tumour cells in primary tumours and synchronously excised lymph node
metastases were very similar. pNR-2 expression showed an unexpected positive association with lymph node
metastasis. We were unable to find any significant association between pNR-2 immunohistochemical staining
and either time to relapse or overall survival. There was a significant association between pNR-2 expression in
primary tumours and response to endocrine therapy on relapse: positive pNR-2 immunohistochemical staining
in primary tumours is predictive of response to hormonal therapy on relapse.
Breast cancer remains one of the major causes ofmortality of
women in the developed world. The growth of a proportion
of breast tumours is dependent upon oestrogens and oestro-
gens stimulate the proliferation of oestrogen receptor positive
breast cancer cells in culture (Lippman & Bolan, 1975).
Hormonal therapy is commonly used to manage breast
cancer, particularly on relapse: it is also being used increas-
ingly as primary therapy, instead of surgery. Not all tumours
respond, and there would be considerable clinical advantage
in accurate prediction of the hormonal response in individual
patients. Oestrogens act via the oestrogen receptor, and
oestrogen receptor status is of predictive value (McGuire et
al., 1975). Measurement of the progesterone receptor, which
is induced by oestrogens, provides additional predictive in-
formation (Osborne et al., 1980). However, 23% of patients
whose tumours express both receptors do not respond to
hormonal therapy, and 11% of patients whose tumours ex-
press neither receptor do respond (Osborne et al., 1980).
Measurement of both receptors is largely reliant upon the
availability of relatively large amounts of fresh tissue for
biochemical assays: although immunohistochemical techni-
ques are becoming more widely available, fresh frozen tissue
is often required (McClelland et al., 1990). There is clearly a
need for additional reliable markers of endocrine response
which can be assessed simply in routine histological prepara-
tions.
Recently, oestrogen-regulated messenger RNAs have been
isolated by differential screening of cDNA libraries from
oestrogen responsive breast cancer cell lines (May & Westley,
1986, 1988; Westley & May, 1987). These mRNAs include
the pNR-2 RNA which corresponds to the pS2 RNA (Mas-
iakowski et al., 1982), the BCEI RNA (Prud'homme et al.,
1985) and the Md2 RNA (Skilton et al., 1989). It is speci-
fically regulated by oestrogens in the oestrogen responsive
MCF-7, ZR 75, T47D (May & Westley, 1988) and EFM-19
(Westley et al., 1989) cell lines, but is not detected in breast
cancer cell lines that do not respond to oestrogens. In sur-
gically resected breast tumours, expression of pNR-2 mRNA
is entirely dependent upon expression of oestrogen receptor
mRNA (Henry et al., 1990): studies of pS2 and oestrogen
receptor proteins in cytosols extracted from breast tumours
have produced similar results (Foekens et al., 1990). Thus
pNR-2/pS2 is a candidate marker of oestrogen response in
human breast cancer.
The pNR-2/pS2 protein is secreted by breast cancer cells
(Nunez et al., 1987). Its function is as yet unknown, but the
deduced amino acid sequence of the pNR-2/pS2 protein
(Jakowlew et al., 1984; Prud'homme et al., 1985; Piggott et
al. in press) suggests that it codes for a small cysteine rich
protein with features reminiscent of small protein growth
factors such as insulin-like growth factor I. Recently it has
been shown to have close homology to porcine pancreatic
spasmolytic polypeptide (Rio et al., 1988) which has growth
stimulatory effects on breast cancer cells in culture (Hoosein
et al., 1989).
In this report we describe the use of a polyclonal antiserum
raised against the C-terminal portion of the pNR-2 protein
(Piggott et al. in press) in an immunohistochemical study of
pNR-2 expression in a series of 172 surgically resected breast
cancers. This is the first study to consider the relationship
between pNR-2 immunohistochemical staining and other
prognostically important factors. The correlation of pNR-2
expression in primary breast cancers with response to hor-
monal therapy on relapse is also addressed for the first time.
Materials and methods
Patients, tumours and statistical analysis
Tumours from 172 patients with primary carcinoma of the
breast were studied. All patients were initially treated by
surgical tumour resection between 1983 and 1987. Most
patients were treated by local excision and most patients with
confirmed lymph node metastasis received postoperative
radiotherapy. Twenty-three patients received adjuvant tamox-
ifen therapy; none of the patients received adjuvant chemo-
therapy. One hundred and fifty-three of the tumours studied
were invasive ductal carcinomas of breast; the remainder
comprised ten invasive lobular carcinomas, five colloid
(mucinous) carcinomas, two tubular carcinomas, one medul-
lary carcinoma and one carcinoid tumour. Patients were
followed clinically for up to 85 months (median = 40
months) or until death. Clinical details were obtained by
scrutiny of the patient's records: the minimum criterion for
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response to hormonal therapy on relapse was disease which
did not progress for at least 6 months. Samples of fresh
tumour tissue were taken at the time of primary surgery for
oestrogen receptor assay by dextran coated charcoal ligand
binding assay as described previously (Henry et al., 1988).
Statistical analysis was performed using the programme CSS
(Statsoft, USA): survival was analysed using the Log-Rank
test (Peto et al., 1977).
Immunohistochemnical staining
Tumour specimens were fixed in phosphate buffered 4%
formalin for a minimum of 24 h and representative blocks
selected: these blocks were further fixed in formal sublimate
(saturated aqueous mercuric chloride and 40% formalde-
hyde, 9:1) for approximately 3 h. After dehydration through
graded percentages of ethanol and then xylene, the tissue was
embedded in paraffin wax. Three iLm sections were cut onto
poly-l-lysine coated slides for immunohistochemical staining.
Sections were stained immunohistochemically using a dia-
minobenzidine peroxidase-antiperoxidase technique (Stern-
berger et al., 1970) as described previously (Piggott et al. in
press). The primary antiserum was a rabbit polyclonal anti-
serum raised against a 31 amino acid synthetic peptide cor-
responding to the C-terminus of the pNR-2 protein: this
primary antiserum was used at 1/200 dilution after digestion
of the section in 0.1% trypsin for 10 min at 37°C. Negative
controls were performed for each section and comprised
omission of the primary, and both the primary and the
secondary antisera. A tumour known to stain positively was
included in each batch of staining as a positive control.
The specificity of the staining was confirmed by preabsorp-
tion of the antiserum. Prior to the standard immunohisto-
chemical procedure, the antiserum was incubated for 1 h at
37°C and then overnight at 4°C in the presence of the syn-
thetic peptide (0.625 gml-').
Scoring ofpNR-2 immunohistochemical staining in breast
tumours
The percentage of breast cancer cells showing a positive
immunohistochemical reaction in a representative section of
each tumour was determined by counting the number of
positively staining cells in a minimum of 2,000 tumour cells
in randomly selected fields. One observer counted all stained
sections and a random sample of sections was counted by a
second observer to confirm reproducibility. Only cells
demonstrating unequivocal staining were considered positive.
Results
pNR-2 immunohistochemical staining in breast cancer
A series of 172 primary breast tumours was stained immuno-
histochemically with a polyclonal antibody to pNR-2. Un-
equivocal pNR-2 staining was present in 117 (68%) of these
tumours. The staining was cytoplasmic, with a tendency to
perinuclear condensation (Figure 1). Cells in both invasive
carcinoma and carcinoma in situ stained. In most positively
staining tumours, stained tumour cells were found scattered
uniformly throughout the tumour, but in some instances the
staining was more focal, suggesting clonal outgrowth. Gener-
ally, positive tumour cells were stained either moderately or
intensely positive. Specific staining was only seen in breast
cancer cells: a variable amount of background staining was
present in the tumour stroma and in vascular smooth muscle,
but it most cases this was only slight. Preabsorption of the
antiserum with the peptide used for immunisation (0.625 Ig
ml-') abolished immunohistochemical staining (Figure lb).
The percentage of pNR-2 positive tumour cells varied
greatly, ranging from less that 1% to 81% (Figure 2). The
mean percentage, for positively staining tumours was 14.9%.
The median percentage, for all tumours, was 3% and this has
been used as the threshold for pNR-2 positivity in most
comparisons. The majority ofpositively stained tumours con-
tained small percentages of pNR-2 positive cells (60% con-
tained less than 10% positive cells: Figure ic, 5% positive).
Examples of three tumours containing different percentages
of pNR-2 positive cells are shown in Figure 1. In six
tumours, pNR-2 expression was detected in the majority of
the tumour cells (Figure Id, 81% positive).
pNR-2 expression and tumour histologicalsubtype
One hundred and fifty-three of the 172 tumours were invasive
ductal caircinomas and 101 of these contained cells staining
positively for pNR-2. The number of tumours in each of the
special histological subtypes was insufficient for meaningful
statistical analysis, but it is interesting to note that nine of
the ten lobular carcinomas stained for pNR-2 (five exceeded
10% positivity and one of these had 81% positively staining
cells; example shown in Figure Id). All of the mucinous
carcinomas stained positively (three at levels exceeding 10%
of cells). The carcinoid tumour and one of the tubular car-
cinomas contained positively staining cells: the medullary
carcinoma was negative.
Association ofpNR-2 staining with oestrogen receptor status
Oestrogen receptor levels, as determined by a cytosolic ligand
binding assay, were available for all of the tumours studied.
Tumours containing in excess of 5 fmol oestrogen receptor
protein per mg cytosol protein were considered to be oes-
trogen receptor positive. There was a highly significant
association between positive oestrogen receptor status and
immunohistochemical staining for pNR-2 (Table I, chi
square= 7.57, P<0.01). Sixty percent of oestrogen receptor
positive tumours were pNR-2 positive (>4% positively
staining cells), compared to only 39% of oestrogen receptor
negative tumours. The positive association between pNR-2
expression and oestrogen receptor status was statistically
significant using cut-offs for pNR-2 positivity from 1% to
6% positively staining cells, but became progressively less
significant as the percentage increased. There was no statis-
tically significant association between pNR-2 expression and
oestrogen receptor status for cut-off values of pNR-2 positi-
vity greater than or equal to 7% positively staining cells. A
weak rank correlation was found between the level of oestro-
gen receptor protein and the proportion of tumour cells
staining positively for pNR-2 (Rs = 0.2, P<0.01).
pNR-2 expression andmenopausal status.
Accurate information on the menopausal status of 160
patients was available. Patients aged less than 55 who had
undergone a hysterectomy and perimenopausal women
whose tumours had been resected within 1 year of last men-
struation were excluded from this analysis. Tumours came
from 44 premenopausal and 116 postmenopausal women.
There was no significant association between menopausal
status and pNR-2 expression when the median level of pNR-
2 expression was chosen for defining pNR-2 positive
tumours. Tumours from premenopausal women were, how-
ever, significantly more likely to contain high percentages
(10% or more) of cells staining positively for pNR-2: 41% of
the 44 tumours from premenopausal women expressed pNR-2
in 10% or more of cells, as compared to only 21% of the
tumours from postmenopausal women (chi square = 6.74,
P<0.01). This relationship was still more significant if only
oestrogen receptor positive tumours were considered in the
analysis (chi square (Yates correction) = 9.41, P<0.005;
Figure 3). The mean percentage of tumour cells expressing
pNR-2 was also higher in oestrogen receptor positive
tumours from premenopausal women (14.8%) as opposed to
postmenopausal women (9.15%, Figure 3): this was statis-
tically significant (Mann-Whitney U Test, P<0.025). There
was no significant relationship between pNR-2 expression
and menopausal status in oestrogen receptor negative
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Figure 1 a, pNR-2 immunohistochemical staining in a field selected from a tumour with 27% positively staining cells overall.
b, Staining in the same tumour after preabsorption of the antiserum with synthetic peptide. c, Staining in a more typical carcinoma
in which 5% of tumour cells stained. d, Staining in a lobular carcinoma in which 81% of tumour cells stained.
pNR-2 expression and tumour histological grade
Tumour histological grade in invasive ductal carcinomas was
assessed using Elston's modification of the method of Bloom
and Richardson (Elston, 1987). Bloom and Richardson's
grade was determined for 151 tumours: there were 16 grade 1
tumours, 58 grade 2 tumours and 77 grade 3 tumours. There
was a significant association between histological grade and
pNR-2 expression: well differentiated (low histological grade)
tumours were more likely to be pNR-2 positive (>4%
positively staining cells), while a higher proportion of poorly
differentiated tumours were pNR-2 negative (chi square=
6.04, P<0.05, Figure 4).
pNR-2 expression and tumour size
Reliable measurements of greatest tumour dimension were
available for 165 of the tumours studied. Greatest dimension
ranged from 9 mm to 170 mm with a medium of 26 mm; for
purposes of analysis tumours that were less than the median
tumour diameter have been considered small. There was a
significant correlation between smaller tumour size and pNR-2
expression. Seventy-nine tumours measured 26 mm or less in
diameter and of these 45 (57%) were pNR-2 positive (>4%
positively staining cells), while only 36 (42%) of the 86
tumours measuring greater than 26 mm in diameter were
pNR-2 positive (chi square = 3.76, P = 0.05). pNR-2 positive618 J.A. HENRY et al.
tumours were on average smaller (mean = 30.6 mm) than
negative tumours (mean = 35.3 mm) and these values were
significantly different (Mann-Whitney U Test, P<0.025).
The mean diameters remained significantly different even
after removal of tumours with no positively staining cells
from the analysis (P<0.05).
pNR-2 expression and lymph node metastasis
The possibility of a correlation between pNR-2 expression
and lymph node metastases was considered. Accurate histo-
logical assessment of lymph node metastasis was possible in
104 cases. Forty-eight of the axillary node samples were free
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Figure 4 pNR-2 immunohistochemical staining and tumour
differentiation (Bloom and Richardson's grade). There was a
significant association between low tumour grade (better differ-
entiation) and pNR-2 immunohistochemical staining in >4% of
tumour cells (chi square = 6.04, P<0.05).
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Figure 2 Distribution of the percentage of pNR-2 positive cells
in the 172 tumours. Fifty-six tumours did not stain for pNR-2
and the majority of the remainder contained only small percent-
ages of positive cells. The median percentage was 3% positive
cells.
Table I Comparison of oestrogen receptor status and pNR-2
immunohistochemical staining
Oestrogen receptor status
<5fmolmg >5fmolmg
pNR-2 staining protein protein
<4% + ve tumour cells 40 16
>4% + ve tumour cells 43 73
Chi square = 7.57, P<0.01.
Menopausal status
Figure 3 The percentages of pNR-2 positive tumour cells in
oestrogen receptor positive tumours from pre- and post-meno-
pausal patients. A significantly higher proportion of tumours
from premenopausal women contained > 10% positive staining
tumour cells than did those from postmenopausal women (chi
square= 9.41, P<0.005) and the mean percentage of pNR-2
positive cells was higher in tumours arising premenopausally
(bars indicate means).
of tumour: in the other 56 cases lymph node metastasis was
confirmed. There was no significant association between
pNR-2 staining (>4% positively staining cells) and the
presence or absence of lymph node metastasis. Interestingly,
however, if the threshold for positive pNR-2 staining was
lowered to >1% positive tumour cells, there was a signi-
ficant association between pNR-2 expression and nodal
metastasis: 42 of 67 (63%) of pNR-2 positive tumours had
metastasised, as opposed to only 14 of 37 (38%) of pNR-2
negative tumours (chi square= 5.92, P< 0.025). In tumours
expressing pNR-2 the mean percentage of positively staining
tumour cells was higher in tumours with lymph node metas-
tases (13.3%) than in those which had not metastasised
(7.3%): this was statistically significant (Mann-Whitney U
test, P= 0.0005). There was no significant association
between oestrogen receptor status and the presence or
absence of lymph node metastasis. Larger tumours (belong-
ing to the upper three quartiles of tumour diameter) were
significantly more likely to have metastasised to axillary
lymph nodes (chi square (Yates) = 7.93, P= 0.005).
pNR-2 expression in primary tumours and lymph node
metastases
Sections of lymph nodes containing metastatic tumour from
50 patients, which had been excised at the same time as the
primary tumours, were stained for pNR-2. There was a
highly significant correlation between pNR-2 expression in
primary tumours and metastatic deposits (chi square = 24.27,
P<0.001): only three cases contained positively staining cells
in the primary tumour but not the lymph node metastases
and only two cases contained positively staining cells in the
metastases but not the primaries. There was also a highly
significant correlation between the proportion of positively
staining cells in the metastatic deposits and primary tumours
(Figure 5, Spearman's Rank Order Correlation = 0.81, P<
0.00001). Omission of cases where both the primary tumour
and metastatic deposit contained no pNR-2 positive cells did
not greatly reduce the significance of this correlation (Rs=
0.663, P<0.00001). The proportion of positively staining
cells in a primary tumour is therefore a good predictor of
expression in metastatic deposits.
pNR-2 expression related to time to relapse and overall
survival
The influence of immunohistochemically detectable pNR-2
expression on overall post-surgical survival and time to first
relapse was examined. There was no evidence of a statis-
tically significant correlation of pNR-2 expression in any
proportion of tumour cells with either time to relapse or
overall survival: Figure 6 shows a representative survival
comparison. Subgroups of oestrogen receptor positive and
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Figure 5 pNR-2 staining in primary tumours and lymph node
metastases. The correlation between the percentage of positive
tumour cells in primary tumours and synchronously excised
lymph node metastases was significant (Rs=0.81, P< 0.00001).
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Figure 6 pNR-2 immunohistochemical staining and overall sur-
vival. There was no significant difference in overall survival when
patients with tumours which contained >-4% positive cells were
compared to those whose tumours expressed pNR-2 in lower
percentages of cells.
negative cases and lymph node positive and negative cases
were also examined for evidence of any significant effect of
pNR-2 expressxion on survival but no correlation was found.
Prognosis was however significantly better in patients with
oestrogen receptor positive tumours than oestrogen receptor
negative tumours with regard to both time to first relapse
(Log-Rank test, P<0.05) and overall survival (P<0.025).
Patients with lymph node metastases at presentation had a
poorer prognosis in terms of time to first relapse (Log-Rank
Test, P<0.001) and overall survival (P<0.0001).
pNR-2 expression andprediction ofresponse to endocrine
therapy
A group of 55 women received endocrine therapy on relapse.
Thirty-five of these women were postmenopausal and all but
one received the antioestrogen tamoxifen as primary treat-
ment on relapse, the remaining woman receiving primary
aminoglutethimide. Twelve of these women received second
line endocrine therapy after failing to respond to tamoxifen
(aminoglutethimide or medroxyprogesterone acetate). Seven-
teen premenopausal women also received endocrine therapy
on relapse, but as they formed a rather heterogeneous group
both in terms of type of endocrine therapy (oophoretomy
alone, oophorectomy plus tamoxifen, tamoxifen alone and
aminoglutethimide alone) and previous therapy (many had
received chemotherapy) they were not analysed further. A
further three women whose menopausal status could not be
defined were treated hormonally but have been excluded
from further analysis.
The value of pNR-2 immunohistochemical staining for
predicting response to endocrine therapy on relapse was
examined in the group of 35 postmenopausal patients. In 21
of the 35 women, disease progressed despite endocrine
therapy. The remaining 14 women responded to at least one
modality of endocrine therapy for times ranging from 6-48
months. There was a significant association between pNR-2
immunohistochemical staining in the primary tumour and
subsequent hormonal response. In eight of 12 (67%) women
whose tumours were pNR-2 positive (>4% positively stain-
ing cells) there was a worthwhile response to endocrine
therapy on relapse: in contrast, only six of 23 (26%) of
women whose tumours were pNR-2 negative (<4% posi-
tively stained cells) benefitted from endocrine therapy (Fisher
Exact Probability = 0.025). The association between pNR-2
immunohistochemical staining and hormonal response was
significant for a range of cut-off values for pNR-2 positivity
(1-5% positively staining cells, Figure 7) lower cut-off values
for pNR-2 positivity increased the accuracy of predicting a
lack of response in the pNR-2 negative group (only 17%
responded using a cut-off of >1%, Figure 7) but at the
expense of reducing the accuracy of predicting a response in
the pNR-2 positive group (52% responded using a cut-off of
> 1% compared to 70% using a cut-off of >5%; Figure 7).
Higher cut-offs increased the proportion of responders in the
pNR-2 positive group. In this group of patients, the oest-
rogen receptor status of the primary tumour was not
significantly associated with response to hormonal therapy on
relapse: four of 15 oestrogen receptor negative tumours
responded to hormonal therapy on relapse, as compared to
10 of 20 oestrogen receptor positive tumours (Fisher's Exact
Probability = 0.15).
Discussion
There has been considerable interest in detection of the
oestrogen receptor and oestrogen-regulated genes and pro-
teins in breast cancer, both for studying the biology of breast
cancer and for predicting response to endocrine therapy in
breast cancer. The pNR-2/pS2 gene was discovered as a
result of its oestrogen regulation in cell lines derived from
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Figure 7 pNR-2 immunohistochemical staining and response to
hormonal therapy on relapse. There was a significant association
between positive pNR-2 immunohistochemical staining and re-
sponse to hormonal therapy over cut-off values for pNR-2 posi-
tivity ranging from 1% to 5%. The figures above the columns
indicate the percentage of responders in each group.
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human breast cancer (Masiakowski et al., 1982; Prud'homme
et al., 1985; May & Westley, 1986). The pNR-2/pS2 gene has
an oestrogen-responsive regulatory element in the 5' non-
coding region (Berry et al., 1989) and the mRNA is only
found in breast cancer cell lines that express oestrogen recep-
tor (May & Westley, 1988). Transcription of the pNR-2/pS2
gene is a primary response to oestrogens (Brown et al., 1984)
and gene transcription is largely antagonised by the antioes-
trogen tamoxifen (May & Westley, 1987). Previous studies of
pNR-2/pS2 expression in breast cancer have considered levels
of pNR-2/pS2 mRNA in extracts of surgically resected
tumour specimens (Rio et al., 1987; Skilton et al., 1989;
Henry et al., 1990) and have shown a good correlation with
oestrogen receptor expression. A more recent study (Foekens
et al., 1990) measured levels of pNR-2/pS2 protein in breast
cancer cytosols, with similar results. In this study, we have
used immunohistochemistry to demonstrate expression of the
pNR-2/pS2 protein retrospectively in an archival series of
breast cancers using a rabbit polyclonal antiserum raised
against a peptide derived from the C-terminal portion of the
predicted sequence of the pNR-2/pS2 protein (Piggott et al.
in press). An advantage of immunohistochemical techniques
over biochemical assays on tissue extracts is that the spatial
localisation of the pNR-2/pS2 protein is determined, allowing
assessment of both intratumoural heterogeneity of expression
and of expression by cells other than cancer cells. Immuno-
histochemical techniques do not however allow precise quan-
tification of levels of expression.
Specific immunohistochemical staining for pNR-2/pS2 was
confined to breast cancer cells: the tumour stroma and
associated lymphohistiocytic infiltrate showed at most low,
background levels of staining. Tumour cell staining was cyto-
plasmic and showed a tendency to perinuclear accentuation,
in agreement with the pattern recorded by Rio et al. (1987):
we have found no evidence of the plasma membrane staining
described by Prud'homme et al. (1990). Individual tumours
exhibited considerable heterogeneity of staining and in most
tumours only a relatively small proportion of cancer cells
scattered throughout the tumour stained (Figures 1 and 2).
Rio et al. (1987) found a similar heterogeneity of staining.
There was however little variation in the intensity of staining
in positive tumour cells, most of which exhibited moderately
intense staining. While it is possible that the small proportion
of cells staining reflects the insensitivity of immunohisto-
chemistry, it is equally possible that only a small proportion
of tumour cells express pNR-2. The remainder may not
express the protein because they lack the oestrogen receptor
or because there is intratumoural heterogeneity of respon-
siveness to receptor mediated signals: double labelling studies
with antibodies to both oestrogen receptor and pNR-2 would
clarify this point. On a more speculative note, it is possible
that expression in the majority of cells is suppressed by
dominant cells expressing high levels of the protein. Hetero-
geneity of oestrogen receptor levels has been demonstrated
biochemically in different areas of the same tumour (van
Netten et al., 1985) and immunohistochemically, in different
cells (King et al., 1985). Immunohistochemical staining of
other oestrogen-regulated proteins such as progesterone re-
ceptor (Soomro & Shousha, 1990) and the Mr 24,000 protein
(Anderson et al., 1989) also appears heterogeneous in breast
cancer.
pNR-2 immunohistochemical staining was significantly
associated with positive oestrogen receptor status (defined by
a 5 fmol mg-' cytosolic protein threshold in a dextran coated
charcoal ligand binding assay). The majority of oestrogen
receptor positive tumours were also pNR-2 positive (Table I).
However, 39% of the oestrogen receptor 'negative' tumours
were pNR-2 positive. The apparent expression of pNR-2 by
oestrogen receptor 'negative' tumours is probably due to the
relative insensitivity of cytosolic ligand binding assays and
the somewhat arbitrary nature of rigid cut-off points for
oestrogen receptor positivity rather than constitutive non-
oestrogen regulated pNR-2 expression in breast cancer cells.
Using highly sensitive Northern transfer techniques, we have
detected oestrogen receptor mRNA expression in a much
larger proportion of tumours than considered positive by
ligand binding assay (Henry et al., 1988). When techniques of
comparable sensitivity are used to detect oestrogen receptor
and pNR-2 expression it is evident that expression of pNR-2
in breast cancer in the absence of oestrogen receptor is an
extremely rare event (Rio et al., 1987; Henry et al., 1990).
With regard to the oestrogen regulation of pNR-2, it is also
interesting to note that a high proportion of the lobular
carcinomas expressed pNR-2, often in a large proportion of
cells. Lobular carcinomas of breast show a more marked
tendency to express oestrogen receptor than the more com-
mon ductal carcinoma (Rosen et al., 1978; McCarty et al.,
1980).
Further support for the oestrogen regulation of pNR-2 in
breast cancer may be derived from the comparison of pNR-2
immunohistochemical staining in tumours from premeno-
pausal and postmenopausal women. Oestrogen receptor posi-
tive tumours from premenopausal women were significantly
more likely to express pNR-2 in a high proportion of tumour
cells and the mean number of positively staining cells in
tumours arising premenopausally was also significantly
higher. It is likely that these differences relate to the higher
levels of circulating oestrogens found premenopausally
(Siiteri et al., 1986). There were no significant differences in
the proportion of oestrogen receptor positive and negative
tumours in the premenopausal and postmenopausal groups,
and mean levels of oestrogen receptor did not differ in the
two groups (data not shown). Higher levels of pNR-2/pS2
have also been recorded in cytosolic extracts of tumours from
premenopausal women by Foekens et al. (1990).
The possibility of an association between immunohisto-
chemically detectable pNR-2 expression and other prognos-
tically important factors was also investigated. Positive
immunohistochemical staining for pNR-2 was significantly
associated with both small tumour size and better tumour
differentiation, both of which are acknowledged to be mark-
ers of favourable prognosis (Hawkins et al., 1987; Alexieva-
Figusch et al., 1988; Elston, 1987). Positive oestrogen recep-
tor status has previously been shown to associate with low
histological grade (McCarty et al., 1980; Hawkins et al.,
1987) but correlations with tumour size are not well recog-
nised: in the current series the correlation between oestrogen
receptor status and tumour grade fell short of significance,
but there was a significant association between positive oest-
rogen receptor status and smaller tumour size (data not
shown). There was no evidence of any association between
parity and pNR-2 staining.
Although there was no evidence of any significant associa-
tion between pNR-2 immunohistochemical staining and
lymph node metastasis when the median percentage of posi-
tively staining cells was used as the cut-off point, there was a
significant association between pNR-2 staining and lymph
node metastasis if > 1% positively staining tumour cells was
used as the threshold for pNR-2 positivity. Using this thres-
hold, pNR-2 positive tumours were significantly more likely
to have metastasised to lymph nodes than pNR-2 negative
tumours. This finding is paradoxical in view of the associa-
tion of pNR-2 immunohistochemical staining with the
favourable prognostic features listed above: confirmed lymph
node metastasis is the most important predictor of poor
prognosis (Hawkins et al., 1987; Alexieva-Figusch et al.,
1987). The reason for the association between pNR-2 expres-
sion and lymph node metastasis is unclear, but it is interest-
ing to note that the pNR-2/pS2 protein has structural
features similar to some small protein growth factors and
shows close homology to pancreatic spasmolytic polypeptide,
which has been shown to have growth stimulatory effects on
MCF-7 breast cancer cells in culture (Hoosein et al., 1989).
The pNR-2/pS2 protein may also function as a growth factor
implicated in the repair of damaged gastro-intestinal epithe-
lium (Wright et al., 1991). It is therefore possible that pNR-2,
despite its other prognostically favourable associations, is an
oestrogen regulated growth factor, able to facilitate lymph
node metastasis. This would suggest that expression of pNR-2
in only small numbers of cells is sufficient to affect thepNR-2 IMMUNOHISTOCHEMICAL STAINING IN BREAST CANCER 621
growth and metastatic potential of a tumour, possibly by
paracrine effects on other tumours cells.
We were unable to demonstrate any association between
pNR-2 immunohistochemical staining and overall survival or
time to first relapse, despite the association of pNR-2 expres-
sion with other prognostic indicators. In this respect, our
results differ from those of Foekens et al. (1990), who found
that pNR-2/pS2 expression in breast cancer was associated
with a longer time to recurrence and death. The reason for
this difference is unclear, but it may relate to differences in
either the techniques used to measure pNR-2/pS2 or differ-
ences in the patient groups studied. Problems ofquantitation
are inherent to immunohistochemical techniques: although it
is possible to reliably assess the proportion ofcells expressing
an antigen, quantitation of levels of expression is at best
subjective. Foekens et al. (1990) used a quantitative immuno-
radiometric cytosolic assay to define groups of tumours con-
taining different levels of pNR-2/pS2. Foekens et al. (1990)
used a cut-off level of 11 ngmg' protein to define pNR-2/
pS2 positivity and hence only approximately 25% of tumours
were considered positive; however, using a similarly high
cut-off (to give 25% pNR-2 positive tumours) we were un-
able to demonstrate any association with survival. It will be
valuable to compare levels of pNR-2 in cytosolic extracts of
tumours with the pattern ofimmunohistochemical staining in
sections of the same tumours. We are unaware of any signi-
ficant differences in the patient groups considered in the two
studies, apart for the extensive use ofadjuvant chemotherapy
in the group studied by Foekens et al. (1990).
We have previously shown that the response of breast
tumours to primary tamoxifen is associated with the presence
of pNR-2 mRNA in the excised tumour (Henry et al., 1990).
In this study we have demonstrated that there is a significant
association between pNR-2 expression in primary tumours
and response to hormonal therapy on relapse. The capacity
of a measurement made on a primary tumour to predict the
response of metastatic tumour cells depends on the primary
tumour and metastatic deposit having similar phenotypes. It
is therefore important that in this study we have shown that
levels of pNR-2 expression in primary tumours correlated
closely with (and hence were predictive of) levels of pNR-2
expression in synchronously excised deposits of tumour pre-
sent in axillary nodes.
pNR-2 expression was significantly associated with re-
sponse to hormonal therapy in a group of 35 postmeno-
pausal women receiving endocrine therapy as first treatment
on relapse. This association was most significant if a thres-
hold of >4% positive staining cells was used, but significant
associations were obtained over a range of thresholds from
1% to 5% (Figure 7). Lowering the threshold for pNR-2
positivity increased the accuracy ofpredicting non-responders
in the pNR-2 negative group but decreased the accuracy of
predicting responders in the pNR-2 positive group. In con-
trast, higher thresholds increased the accuracy of predicting
responders in the pNR-2 positive group but slightly reduced
the accuracy of predicting non-responders in the pNR-2
negative group. The optimum threshold of pNR-2 positivity
for prediction of hormonal responsiveness remains to be
determined, but is likely to vary depending upon the clinical
context (e.g.:- whether predicting the response of a primary
tumour to primary endocrine therapy, or the response of
metastatic tumour to endocrine therapy on first relapse).
In general, the capacity of pNR-2 immunohistochemical
staining to predict hormonal response on relapse is similar to
that described for oestrogen receptor and progesterone recep-
tor either singly or in combination in other series (Mourisden
et al., 1978; Osborne et al., 1980), where objective responses
to endocrine therapy were obtained after relapse in more
than half of the receptor positive tumours but were rare in
receptor negative tumours. pNR-2 immunohistochemical
staining has advantages over detection of both receptors in
that it is applicable to routinely formalin fixed and processed
paraffin embedded histological material, eliminating the need
to prepare cytosol. Although an immunohistochemical tech-
nique has been used to detect oestrogen receptor in frozen
sections of breast tumours and predict response to hormonal
therapy (McClelland et al., 1990) this is not applicable to
fixed tissue.
In conclusion, although the precise function of the pNR-2/
pS2 protein remains unclear, there is a mounting body of
evidence to suggest that it may be a growth factor. This is of
interest in view of the capacity of antioestrogens to anta-
gonise oestrogen mediated induction of pNR-2 expression in
breast cancer cell lines in vitro (May & Westley, 1987; John-
son et al., 1989), suggesting a rational basis for antioestrogen
therapy. The value of pNR-2 as a predictor of hormonal
response in breast cancer merits further study and prospec-
tive studies will be particularly informative.
This work was supported by the North of England Cancer Research
Campaign, the Wellcome Trust, the Breast Cancer Research Trust,
the Gunnar Nilsson Cancer Research Trust and the Medical
Research Council. We thank Ms S. Cousen for peptide synthesis,
Mrs D. Levett for performing the immunohistochemistry, Mrs P.
Chambers for undertaking the oestrogen receptor assay, Mrs R.
Brown for technical assistance and Mr S. Brabazon for photographic
assistance. F.E.B. May thanks the Royal Society for a 1983 Univer-
sity Research Fellowship.
References
ALEXIEVA-FIGUSCH, J., VAN PUTTEN, W.L.J., BLANKENSTEIN,
M.A., BLONK-vAN DER WIST, J. & KLIJN, J.G.M. (1988). The prog-
nostic value and relationships of patient characteristics, estrogen
and progestin receptors, and site of relapse in primary breast
cancer. Cancer, 61, 758.
ANDERSEN, J., SKOVBON, H. & POULSEN, H.S. (1989). Immuno-
cytochemical determination of the estrogen-regulated protein
Mr24,000 in primary breast cancer and response to endocrine
therapy. Eur. J. Cancer Clin. Oncol., 25, 644.
BERRY, M., NUNEZ, A.M. & CHAMBON, P. (1989). Estrogen-respon-
sive element of the human pS2 gene is an imperfect palindromic
sequence. Proc. Nati Acad. Sci. USA, 86, 1218.
BROWN, A.M.C., JELTSCH, J.-M., ROBERTS, M. & CHAMBON, P.
(1984). Activation of pS2 gene transcription is a primary response
to estrogen in the human breast cancer cell line MCF-7. Proc.
Nati Acad. Sci. USA, 81, 6344.
ELSTON, C.W. (1987). Grading of invasive carcinoma of the breast.
In Diagnostic Histopathology of the Breast, Page, D.L. & Ander-
son, T.J. (eds). p. 300. Churchill Livingstone: Edinburgh.
FOEKENS, J.A., RIO, M.-C., SEGUIN, P. & 5 others (1990). Prediction
of relapse and survival in breast cancer patients by pS2 protein
status. Cancer Res.,, 50, 3832.
HAWKINS, R.A., WHITE, G., BUNDRED, N.J. & 4 others (1987).
Prognostic significance of oestrogen and progestagen receptor
activities in breast cancer. Br. J. Surg., 74, 1009.
HENRY, J.A., NICHOLSON, S., FARNDON, J.R., WESTLEY, B.R. &
MAY, F.E.B. (1988). Measurement of oestrogen receptor mRNA
levels in human breast tumours. Br. J. Cancer, 58, 600.
HENRY, J.A., NICHOLSON, S., HENNESSY, C., LENNARD, T.W.J.,
MAY, F.E.B. & WESTLEY, B.R. (1990). Expression ofthe oestrogen
regulated pNR-2 mRNA in human breast cancer: relation to
oestrogen receptor mRNA levels and response to tamoxifen
therapy. Br. J. Cancer, 61, 32.
HOOSEIN, N.M., THIM, L., JORGENSEN, K.H. & BRATTAIN, M.G.
(1989). Growth stimulatory effect of pancreatic spasmolytic poly-
peptide on cultured colon and breast tumour cells. FEBS Lett.,
247, 303.
JAKOWLEW, S.B., BREATHNACH, R., JELTSCH, J.-M., MASIAKOW-
SKI, P. & CHAMBON, P. (1984). Sequence of the pS2 mRNA
induced by estrogen in the human breast cancer cell line MCF-7.
Nucleic Acids Res., 12, 2861.
JOHNSON, M.D., WESTLEY, B.R. & MAY, F.E.B. (1989). Oestrogenic
activity of tamoxifen and its metabolites on gene regulation and
cell proliferation in MCF-7 breast cancer cells. Br. J. Cancer, 59,
727.
KING, W.J., DESOMBRE, E.R., JENSEN, E.V. & GREENE, G.L. (1985).
Comparison of immunocytochemical and steroid-binding assays
for estrogen receptor in human breast tumors. Cancer Res., 45,
293.622 J.A. HENRY et al.
LIPPMAN, M.E. & BOLAN, G. (1975). Oestrogen-responsive human
breast cancer in long term tissue culture. Nature, 256, 592.
MASIAKOWSKI, P., BREATHNACH, R., BLOCH, J., GANNON, R.,
KRUST, A. & CHAMBON, P. (1982). Cloning ofcDNA sequences of
hormone regulated genes from the MCF-7 human breast cancer cell
line. Nucleic Acids Res., 10, 7895.
MAY, F.E.B. & WESTLEY, B.R. (1986). Cloning of estrogen regulated
messenger RNA sequences from human breast cancer cells. Cancer
Res., 46, 6034.
MAY, F.E.B. & WESTLEY, B.R. (1987). Effects of tamoxifen and
4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated
RNAs in human breast cancer cells. J. Biol. Chem., 262, 15894.
MAY, F.E.B. & WESTLEY, B.R. (1988). Identification and characterisa-
tion of estrogen regulated RNAs in human breast cancer cells. J.
Biol. Chem., 263, 12901.
MCCARTY, K.S., BARTON, T.K., FETTER, B.F. & 6 others (1980).
Correlation ofestrogen and progesterone receptors with histologic
differentiation in mammary carcinoma. Cancer, 46, 2851.
McCLELLAND, R.A., FINLAY, P., WALKER, K.J. & 4 others (1990).
Automated quantitation ofimmunocytochemically localised estro-
gen receptors in human breast cancer. Cancer Res., 50, 3545.
McGUIRE, W.L., CARBONNE, P.D. & VOLLMER, R.P. (1975). (eds)
Estrogen Receptor and Human Breast Cancer. Raven Press:New
York.
MOURISDEN, H., PALSHOF, T., PATTERSON, J. & BATTERSBY, L.
(1978). Tamoxifen and advanced breast cancer. Cancer Treat.
Rev., 5, 131.
VAN NETTEN, J.P., ALGARD, F.T., COY, P. & 6 others (1985).
Heterogenous estrogen receptor levels detected via multiple micro-
samples from individual breast cancers. Cancer, 56, 2019.
NUNEZ, A.-M., JAKOWLEV, S., BRIAND, J.-P. & 4 others (1987).
Characterisation oftheestrogen-induced pS2proteinsecretedbythe
human breast cancer cell line MCF-7. Endocrinology, 121, 1759.
OSBORNE, C.K., YACHINOWIZ, M.G., KNIGHT, W.A. &McGUIRE, W.L.
(1980). The value of estrogen and progesterone receptors in the
treatment of breast cancer. Cancer, 46, 2884.
PETO, R., PIKE, M.C., ARMITAGE, P. & 7 others (1977). Design and
analysis of randomised clinical trials requiring prolonged observa-
tion ofeach patient. II. Analysis and examples. Br. J. Cancer, 35, 1.
PIGGOTT, N.H., HENRY, J.A., MAY, F.E.B. & WESTLEY, B.R. (1990).
Antipeptide antibodies against the pNR-2 oestrogen regulated
protein of human breast cancer cells and detection of pNR-2
expression in normal tissues by immunohistochemistry. J. Pathol.
(in press).
PRUD'HOMME,J.-F., FRIDLANSKY, F.,LECUNFF, M.&4others(1985).
Cloning ofageneexpressed inhumanbreastcancerand regulated by
estrogen in MCF-7 cells. DNA, 4, 11.
PRUD'HOMME, J.-F., JOLIVET, A., PICHON, M.-F., SAVOURET, J.-F.
& MILGROM, E. (1990). Monoclonal antibodies against native
and denatured forms of estrogen-induced breast cancer protein
(BCEI/pS2) obtained by expression in Escherichia coli. Cancer
Res., 50, 2390.
RIO, M.C., BELLOCQ, J.P., GAIRARD, B. & 7 others (1987). Specific
expression of the pS2 gene in subclasses of breast cancers in
comparison with expression of the estrogen and progesterone
receptors and the oncogene ERBB2. Proc. Nati Acad. Sci. USA, 84,
9243.
RIO, M.C., BELLOCQ,J.P., DANIEL,J.Y. & 5 others (1988). Breastcancer
associated pS2 protein: synthesis and secretion by normal stomach
mucosa. Science, 241, 705.
ROSEN, P.P., MENENDEZ-BOTET, C.J., SENIE, R.T., SCHWARTZ, M.K.,
SCHOTTENFELD, D. & FARR, G.H. (1978). Estrogen receptor
protein (ERP) and the histopathology of human mammary car-
cinoma. In Hormones, ReceptorsandBreast Cancer, McGuire, W.L.
(ed), p. 71. Raven Press: New York.
SIITERI, P.K., SIMBERG, N. & MURAI, J. (1986). Estrogens and breast
cancer. Ann. NY. Acad. Sci., 464, 100.
SKILTON, R.A., LUQMANI, Y.A., MCCLELLAND, R.A. & COOMBES,
R.C. (1989). Characterisation of a messenger RNA selectively
expressed in human breast cancer. Br. J. Cancer, 60, 168.
SOOMRO, S. & SHOUSHA, S. (1990). Demonstration of progesterone
receptors in paraffin wax sections of breast carcinoma. J. Clin.
Pathol., 43, 671.
STERNBERGER, L.A., HARDY, P.H., CUCULIS, J.J. & MEYER, H.G.
(1970). The unlabelled antibody method ofimmunohistochemistry:
preparation and properties of soluble antigen-antibody complex
(horseradish peroxidase:antiperoxidase) and its use in the identi-
fication of spirochaetes. J. Histochem. Cytochem., 18, 315.
WESTLEY, B.R. & MAY, F.E.B. (1987). Oestrogen regulates cathepsin D
mRNA levels in oestrogen responsive human breast cancer cells.
Nucleic Acids Res., 15, 3773.
WESTLEY, B.R., HOLZEL, F. & MAY, F.E.B. (1989). Effects ofoestrogen
andtheantioestrogens, tamoxifen and LY1 17018, onfouroestrogen
regulated RNAs in the EFM-19 breast cancer cell line. J. Steroid
Biochem., 32, 365.
WRIGHT, N.A., POULSON, R., STAMP, G.W.H. & 6 others (1991).
Epidermal growth factor (EGF/URO) induces expression of
genes encoding regulatory peptides in damaged human gastro-
intestinal tissues. J. Pathol., 162, 279.